Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RO-104
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : RevOpsis Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
RevOpsis and Kemwell Form Strategic Manufacturing Partnership for Biologics
Details : Through the partnership, RevOpsis is well-positioned to advance the clinical development of RO-104, a first-in-class lead candidate for the treatment of neovascular age-related macular degeneration.
Brand Name : RO-104
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 17, 2024
Lead Product(s) : RO-104
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : RevOpsis Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
LOOKING FOR A SUPPLIER?